



## CONTINUING MEDICAL EDUCATION INFORMATION

### MISSION

The purpose of the American Academy of Dermatology (AAD) CME Program is to provide members with opportunities for life-long learning and assistance in fulfilling their maintenance of certification and licensure requirements, thereby promoting excellence in the provision of dermatologic care.

### DEFINITION OF CONTINUING MEDICAL EDUCATION

Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public. *Source: www.accme.org*

### COMMERCIAL BIAS

Content or format in a CME activity or its related materials that promotes the products or business lines of an ineligible company. As described in the Standards for Integrity and Independence in Accredited Continuing Education, providers are responsible for protecting learners from commercial bias and marketing. In addition to preventing influence from ineligible companies, the Standards prohibit faculty from actively promoting or selling products or services that serve their professional or financial interests. *Source: www.accme.org*

### SCIENTIFIC ASSEMBLY COMMITTEE

*\*As of November 10th planning meeting.*

**Hensin Tsao, MD, PhD**  
Chair, 2024 Annual Meeting

**Howard Wooding Rogers, MD,**  
Chair, 2024 Innovation Academy

**George Elgart, MD**

**Kathryn Schwarzenberger, MD**

**Robert Sidbury, MD, MPH**

**Amit Garg, MD,**  
Chair, Council on Education  
**Joslyn S. Kirby, MD,** chair,  
Education Research Committee

**Terrence A. Cronin, Jr., MD,**  
President

**Seemal R. Desai, MD**  
President-Elect

**Daniel D. Bennett, MD,** Secretary-  
Treasurer

**Keyvan Nouri, MD, MBA,** Assistant  
Secretary-Treasurer

**Kevin D. Cooper, MD**  
Chair, Named Lectureship Task Force

**Carmen M. Salavastu, MD,** Chair,  
International Affairs Committee

**Joshua Mervis, MD,** Resident and  
Fellows Committee Representative

**Raj Chovatiya, MD** Young Physician's  
Committee Representative

**Timothy A. Moses, CMP,**  
Senior Director, Meetings &  
Conventions

**Jennifer Thompson, MS,**  
**FACEHP**  
Director, Education

## **STATEMENT OF NEED**

The AAD Innovation Academy is planned to comprehensively address the nine content areas within the Dermatologic Core Curriculum and provide dermatologists and other dermatology health care professionals with high quality educational opportunities for the optimization of dermatologic knowledge, competence and performance.

## **TARGET AUDIENCE**

The target audience of the AAD Innovation Academy are dermatologists and others involved in the delivery of dermatologic care.

## **GLOBAL LEARNING OBJECTIVES**

This comprehensive activity provides learners with opportunities to:

- Describe potential innovations in treatment or technologies intended to transform the practice of dermatology.
- Identify advances in the diagnosis, management and treatment of diseases of the skin, hair, nails, and mucous membranes.
- Assess the relationship of evidence-based diagnostic approaches and therapies with new dermatologic treatment developments.
- Self-assess current practice management skills and develop strategies for improving these skills.
- Apply new procedural skills into everyday practice.
- Demonstrate effective communication skills and techniques to apply with patients.

**NOTE:** Each session has its own specific learning objectives which are included within each session description in the Innovation Academy Mobile App.

---

## **DISCLOSURES**

### **PLANNER DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)**

The following Scientific Assembly Committee members and staff have no financial relationship(s) with ineligible companies relevant to the content of this CME activity:

- |                            |                         |
|----------------------------|-------------------------|
| ▪ Daniel D. Bennett, MD    | ▪ Viviana Rodriguez     |
| ▪ Terrence Cronin, Jr., MD | ▪ Howard Rogers, MD     |
| ▪ George Elgart, MD        | ▪ Jennifer Thompson, MS |
| ▪ Timothy A. Moses, CMP    | ▪ Candi Zabiegala       |
| ▪ Cari Lamberg             |                         |

The following Scientific Assembly Committee members and staff have a financial relationship(s) with ineligible companies to be disclosed to learners:

<b>Planner</b>	<b>Commercial Interest</b>	<b>Role</b>	<b>Compensation</b>
Raj Chovatiya, MD, PhD, FAAD	AbbVie	Consultant	Fees
	AbbVie	Investigator	Grants/Research Funding
	AbbVie	Speaker	Honoraria
		Consultant (1099 relationship)	
	Amgen		Fees
	Apogee Therapeutics	Consultant	Fees
	Arcutis		
	Biotherapeutics	Consultant	Fees
	Arcutis		
	Biotherapeutics	Speaker	Fees
	arGEN-X	Consultant	Fees
	ASLAN		
	Pharmaceuticals	Consultant	Fees
	Beiersdorf, Inc.	Consultant	Fees
	Beiersdorf, Inc.	Speaker	Fees
	Boehringer Ingelheim	Consultant	Fees
	Boehringer Ingelheim	Speaker	Honoraria
	Bristol-Myers Squibb	Consultant	Fees
	Bristol-Myers Squibb	Speaker	Honoraria
	Cara Therapeutics	Consultant	Fees
	Castle Biosciences	Investigator	Grants/Research Funding
	Derm Education	Speaker/Faculty	
	Foundation	Education	Honoraria
	Dermavant Sciences	Consultant	Fees
	Dermavant Sciences	Speaker	Fees
	Eli Lilly and Company	Consultant	Fees
	Eli Lilly and Company	Speaker	Fees
	Eli Lilly and Company	Investigator	Grants/Research Funding
		Consultant (1099 relationship)	
	FIDE		Honoraria
	Foundation for Research & Education of Dermatology	Speaker/Faculty Education	Honoraria

<b>Planner</b>	<b>Commercial Interest</b>	<b>Role</b>	<b>Compensation</b>
Kevin Cooper, MD, FAAD		Consultant (1099 relationship)	Fees
	Galderma	Consultant	Fees
	Genentech, Inc.	Consultant	
	GlaxoSmithKline	Consultant (1099 relationship)	Fees
	Immunology		
	Incyte Corporation	Consultant	Honoraria
	Incyte Corporation	Speaker	Honoraria
	Incyte Corporation	Advisory Board	Honoraria
	Leo Pharma Inc.	Consultant	Fees
	Leo Pharma Inc.	Speaker	Fees
		Consultant (1099 relationship)	Fees
	L'Oreal USA Inc.	Speaker/Faculty	
	Maui Derm	Education	Honoraria
	National Eczema Association	Speaker/Faculty	
		Education	Honoraria
		Consultant (1099 relationship)	Fees
	Nektar Therapeutics		
	Novartis	Speaker	Fees
		Consultant (1099 relationship)	Fees
	Opsidio		
	Pfizer Inc.	Consultant	Fees
	Pfizer Inc.	Speaker	Fees
	Pfizer Inc.	Investigator	Grants/Research Funding
		Consultant (1099 relationship)	Fees
	RAPT Therapeutics		
	Regeneron	Consultant	Fees
	Regeneron	Speaker	Fees
	Regeneron	Investigator	Grants/Research Funding
	Sanofi	Consultant	Fees
	Sanofi	Speaker	Fees
		Consultant (1099 relationship)	Fees
	Sitryx		
	UCB	Consultant	Fees
	UCB	Speaker	Honoraria
	Amgen	Investigator	Grants/Research Funding

<b>Planner</b>	<b>Commercial Interest</b>	<b>Role</b>	<b>Compensation</b>
	Kyowa Kirin	Consultant	Fees
	Leo Pharma Inc	Investigator	Grants/Research Funding
	Mallinckrodt Pharmaceuticals	Consultant (1099 relationship)	Fees
Seemal Desai, MD, FAAD	AbbVie	Consultant	Fees
	AbbVie	Speaker	Fees
	Allergan, Inc	Consultant	Fees
	Almirall	Consultant	Fees
	Amgen	Consultant	Fees
	AOBiome, LLC	Investigator	Grants/Research Funding
	Apogee Therapeutics	Consultant	Fees
	Atacama Therapeutics	Investigator	Grants/Research Funding
	Avita	Consultant	Fees
	Ballature Beauty	Consultant	Fees
	Beiersdorf, Inc.	Consultant	Fees
	Bristol-Myers Squibb	Consultant	Fees
	Candela Corporation	Consultant	Fees
	Cassiopea S.p.A.	Consultant	Fees
	Castle Biosciences	Consultant	Fees
	Cutera, Inc.	Consultant	Fees
	Dermavant Sciences, Inc.	Consultant	Fees
	Dermavant Sciences, Inc.	Investigator	Grants/Research Funding
	Dermira	Consultant	Fees
	Dermira	Speaker	Honoraria
	Eli Lilly and Company	Consultant	Fees
	EPI Health	Consultant	Fees
	Ferndale Laboratories, Inc.	Consultant	Honoraria
	Foamix	Consultant	Fees
	Foundation for Research & Education of Dermatology	Advisory Board	Fees
	Galderma Laboratories, LP	Consultant	Fees

<b>Planner</b>	<b>Commercial Interest</b>	<b>Role</b>	<b>Compensation</b>
	Galderma Laboratories, LP	Speaker	Honoraria
	Global Vitiligo Foundation	Board of Directors	No Compensation Received
	Gore Range Capital	Stockholder	Stock Options
	Gore Range Capital	Consultant	Stock Options
	Hyphens Pharma	Consultant	Fees
	Illuminate Skin Care LLC	Founder	Other Financial Benefit
	Incyte Corporation	Consultant	Fees
	Incyte Corporation	Investigator	Grants/Research Funding
	International Society of Dermatology	Board of Directors	No Compensation Received
	Janssen Pharmaceuticals, Inc	Consultant	Fees
	Johnson and Johnson	Consultant	Fees
	Leo Pharma Inc.	Consultant	Fees
	L'Oreal USA Inc.	Consultant	Fees
	Lyceum Health	Consultant	Fees
	Medscape	Other	Fees
	National Psoriasis Foundation	Other	No Compensation Received
	Ortho Dermatologics	Consultant	Fees
	PDH Holdings LLC	Other	No Compensation Received
	Pfizer Inc.	Consultant	Fees
	Pfizer Inc.	Speaker	Honoraria
	Revision Skincare	Consultant	Fees
	Sanofi/Regeneron	Consultant	Fees
	Scientis	Consultant	Fees
	Scientis	Consultant	Fees
	Skin Science Advisors	Consultant	Fees
	Skin Science Advisors	Consultant	Fees
	SkinMedica, Inc.	Investigator	Grants/Research Funding
	SkinMedica, Inc.	Investigator	Grants/Research Funding
	UCB	Consultant	Fees
	Verrica		
	Pharmaceuticals Inc	Consultant	Fees
	Verrica		
	Pharmaceuticals Inc	Consultant	Fees
	VYNE Therapeutics	Consultant	Fees

<b>Planner</b>	<b>Commercial Support</b>	<b>Role</b>	<b>Compensation</b>
Amit Garg, MD, FAAD	Womens Derm Society	Board of Directors	No Compensation Received
	AbbVie	Advisory Board	Honoraria
	Boehringer Ingelheim	Advisory Board	Honoraria
	Bristol-Myers Squibb	Advisory Board	Honoraria
	Incyte Corporation	Advisory Board	Honoraria
		Consultant (1099 relationship)	
	Insmed Incorporated		Honoraria
	Janssen Pharmaceuticals, Inc	Advisory Board	Honoraria
	Novartis	Consultant	Honoraria
	Pfizer Inc.	Investigator Data Safety Monitoring Board	Grants/Research Funding
Joslyn Kirby, MD, FAAD	Sanofi		Fees
	UCB	Consultant	Honoraria
	Union Therapeutics	Advisory Board	Honoraria
	AbbVie	Speaker	Honoraria
		Employee (w-2 relationship)	
	Incyte Corporation		Salary
	Novartis	Consultant	Fees
Keyvan Nouri, MD, FAAD			Patent royalties or other compensation for Intellectual Property Rights
	Penn State University	Other	
	UCB	Consultant	Fees
	iVeena Delivery Systems-Eye Drug Delivery		
	Pfizer Inc.	Stockholder	No Compensation Received
Kathryn Schwarzenberger, MD, FAAD		Stockholder	No Compensation Received
Robert Sidbury, MD, FAAD		Data Safety Monitoring Board	
	Pfizer Inc.		Fees
Robert Sidbury, MD, FAAD			
	Arcutis, Inc.	Advisory Board	Honoraria
		Speaker/Faculty	
	Beiersdorf, Inc.	Education	Honoraria
	Castle Biosciences	Investigator	Grants/Research Funding

Planner	Commercial Support	Role	Compensation
	Dermavant Sciences, Inc.	Advisory Board	Honoraria
	Dermavent	Advisory Board	Honoraria
	Eli Lilly	Advisory Board	Honoraria
	Galderma Global	Consultant	Honoraria
	Leo Pharma Inc	Advisory Board	Honoraria
	Regeneron Pharmaceuticals, Inc.	Investigator	No Compensation Received
	UCB	Investigator	Grants/Research Funding

**PRIOR TO THE START OF THIS ACTIVITY, ALL RELEVANT FINANCIAL RELATIONSHIPS WERE MITIGATED**

**FACULTY DISCLOSURE OF FINANCIAL RELATIONSHIP(S)**

It is the policy of AAD that all faculty participating in a CME-certified activity are required to disclose to AAD and to learners all financial relationships they have with any ineligible companies in any amount occurring within the past 24 months that could create a conflict of interest<sup>1</sup>. Typically, such relationships would be with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The intent of this disclosure is not to prevent participation in CME-certified educational activities by individuals with a relevant financial relationship with an ineligible company(s), but rather to provide learners with information on which they can make their own determination whether or not said relationship(s) influenced the content of the educational activity.

Faculty disclosure information is located within the description of each individual session in the Innovation Academy Mobile App. Faculty have been asked to also make a verbal disclosure at the start of their presentations supplemented by a disclosure slide in order to verify the accuracy of the disclosure information posted in the session and ensure their disclosure information is shared with the learners PRIOR to the presentation taking place.

**RESOLUTION OF CONFLICTS OF INTEREST**

In accordance with the ACCME Standards for Independence and Integrity in Accredited Continuing Education, the American Academy of Dermatology has implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and mitigate conflicts of interest for all individuals in a position to control the content of this CME activity.

**UNAPPROVED USE DISCLOSURE**

The American Academy of Dermatology requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label (not approved for the indications being discussed), unlabeled (not approved for any indications), experimental, and/or

---

<sup>1</sup> **Conflict of Interest:** When an individual's interests are aligned with those of an ineligible company the interests of the individual are in "conflict" with the interests of the public. *Source: www.accme.org*



investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these products/procedures. If you have questions, contact the medical affairs department of the manufacturer for the most recent approval information. Faculty for this activity will be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

### **INDEPENDENCE IN CME**

The mission of the Academy's continuing medical education program is to improve patient care and health care outcomes by maintaining, developing and enhancing medical knowledge, patient care, interpersonal and communication skills and professionalism. As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME) and in support of this mission, the Academy is dedicated to providing continuing medical education that is independent, fair, balanced, objective and free of commercial bias.

The Academy employs several strategies to ensure these standards will be met. The planning committee members submit and consider their own disclosure information and recuse themselves from planning educational activities should they have conflicts related to the subject area presented. When developing an educational program, the planning committee reviews applications and disclosure of interest forms, along with needs assessment and evaluative data from past activities in order to develop programming. Potential participants are sent detailed guidelines that provide direction on necessary components to ensure independence in continuing medical education activities and to resolve conflict.

### **CONTENT VALIDATION**

Academy educational activities are designed to promote improvements or quality in health care and not promote a specific proprietary business interest or a commercial interest. Presentations and related materials must be based on scientific methods generally accepted by the medical community.

Presentations should be evidence-based and discuss the validity of the evidence upon which they base the opinion(s) (see Sackett et al, BMJ 1996;312:71-2). This ensures the audience that the recommendations are supported by the evidence and contributes to management of any potential conflicts of interest. Further, if the presentation includes discussion of unlabeled or investigational use of a commercial product, this also must be disclosed to the participants. CME must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality.

If CME educational material or content includes trade names, trade names from several companies should be used where available, as opposed to using trade names from just a single company. Educational materials such as slides, abstracts, and handouts cannot contain any advertising or product-group messages.

### **OUTCOMES MEASUREMENT**

Several methods of evaluation are utilized in assessing the educational program. Session directors, speakers, and attendees are all given the opportunity to evaluate the educational content and speaker performance. Included in this process are measures to rate the success of the Academy's policies regarding independence in continuing medical education activities with particular focus on the absence of commercial bias.

In addition, the Academy may review speaker presentations. These data are only used to determine the effectiveness of the Academy's policies and procedures regarding disclosure. Should it be determined that a member of the Academy's educational program violated the Academy's "Policy to Ensure Independence in Continuing Medical Education," the individual may not be asked to participate in future educational programs.

#### **DISCLAIMER**

The American Academy of Dermatology is not responsible for statements made by faculty. Statements or opinions expressed in this program reflect the views of the faculty and do not reflect the official policy of the American Academy of Dermatology. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to the diagnostic, management and treatment options of a specific patient's medical condition.

#### **COMMERCIAL SUPPORT DISCLOSURE**

The following ineligible company provided commercial support for the 2024 Innovation Academy at the time of publication:

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  
*2024 AAD Innovation Academy*

Pfizer, Inc.  
*AAD 2024 Innovation Academy*

UCB  
*2024 AAD Innovation Academy*

#### **ACCREDITATION**

The American Academy of Dermatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### **AMA PRA CATEGORY 1 CREDIT™ DESIGNATION**

The American Academy of Dermatology designates this Other activity (Live activity and Enduring material) for **24.5 AMA PRA Category 1 Credits™**. The American Academy of Dermatology (AAD) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### **WHAT YOU NEED TO DO TO CLAIM CME CREDIT**

CME credit is awarded based on participation in the learning activities. CME credits can be claimed online at [www.aad.org/evals](http://www.aad.org/evals) or in the meeting mobile app. Credit is calculated on a ¼-hour basis and will be reflected on member transcripts within two weeks after the meeting.